Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIA Dose Ranging Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Higher Doses of Rifampicin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis

NCT01392911 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT01392911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01392911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIA Dose Ranging Trial to Evaluate the Safety, Tolerability, Extended Early Bactericidal Activity and Pharmacokinetics of Higher Doses of Rifampicin in Adult Subjects With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
November 30, 2018
Enrollment
128 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis (tb)